Your browser doesn't support javascript.
loading
Advances in biomaterials and regenerative medicine for primary ovarian insufficiency therapy.
Zhang, Sichen; Zhu, Dashuai; Mei, Xuan; Li, Zhenhua; Li, Junlang; Xie, Mengjie; Xie, Halle Jiang Williams; Wang, Shaowei; Cheng, Ke.
Affiliation
  • Zhang S; Department of Gynecology and Obstetrics, Beijing Hospital, National Center of Gerontology, China. No.1 DaHua Road, Dong Dan, Beijing, 100730, PR China.
  • Zhu D; Peking Union Medical College, Chinese Academy of Medical Sciences, Graduate School of Peking Union Medical College, NO.9 Dong Dan Santiao, Beijing, 100730, PR China.
  • Mei X; Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, NC, 27607, USA.
  • Li Z; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695, USA.
  • Li J; Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, NC, 27607, USA.
  • Xie M; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695, USA.
  • Xie HJW; Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, NC, 27607, USA.
  • Wang S; Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh, NC, 27695, USA.
  • Cheng K; Department of Molecular Biomedical Sciences and Comparative Medicine Institute, North Carolina State University, Raleigh, NC, 27607, USA.
Bioact Mater ; 6(7): 1957-1972, 2021 Jul.
Article de En | MEDLINE | ID: mdl-33426370
Primary ovarian insufficiency (POI) is an ovarian dysfunction that affects more than 1 % of women and is characterized by hormone imbalances that afflict women before the age of 40. The typical perimenopausal symptoms result from abnormal levels of sex hormones, especially estrogen. The most prevalent treatment is hormone replacement therapy (HRT), which can relieve symptoms and improve quality of life. However, HRT cannot restore ovarian functions, including secretion, ovulation, and fertility. Recently, as part of a developing field of regenerative medicine, stem cell therapy has been proposed for the treatment of POI. Thus, we recapitulate the literature focusing on the use of stem cells and biomaterials for POI treatment, and sum up the underlying mechanisms of action. A thorough understanding of the work already done can aid in the development of guidelines for future translational applications and clinical trials that aim to cure POI by using regenerative medicine and biomedical engineering strategies.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Guideline Aspects: Patient_preference Langue: En Journal: Bioact Mater Année: 2021 Type de document: Article Pays de publication: Chine

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Guideline Aspects: Patient_preference Langue: En Journal: Bioact Mater Année: 2021 Type de document: Article Pays de publication: Chine